×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Articles

Patti Kellerhouse
This is my survivor story and how my dragon boat involvement continues to help me get through my breast cancer journey.
Brielle Urciuoli
After success in the non-small cell lung cancer space, immunotherapy is finally making waves in the treatment of small cell lung cancer.
Brielle Urciuoli
This infographic explains some of the basics on mantle cell lymphoma, a type of non-Hodgkin lymphoma.
Silas Inman
The FDA has granted LOXO-292 a breakthrough therapy designation for the treatment of patients with RET fusion–positive non–small cell lung cancer (NSCLC) or RET-mutant medullary thyroid cancer (MTC). This designation will expedite the development and review of the drug.
Jessica Skarzynski
A new tool that helps surgeons distinguish healthy tissue from tumor in real-time could change the landscape of surgical ovarian cancer treatment for the better.
 
Katie Kosko
Researchers may have found a potential new way to treat patients with ovarian or lung cancer who had previously failed other treatments, according to early trial findings published in Annals of Oncology.
 
Jessica Skarzynski
Take a look at the top 5 CURE stories of August 2018 in this video. 
Kristie L. Kahl
The Food and Drug Administration (FDA) granted priority review to a new supplemental biologics license application for Keytruda (pembrolizumab) to treat adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma, according to Merck, the agent’s manufacturer.
Kristie L. Kahl
Stromal cells – known to provide structure to one’s organs – found in bladder cancer may explain why some patients do not respond to Opdivo (nivolumab) treatment.
 
Angelica Welch
Some patients eligible for bladder surgery due to cancer may safely opt to preserve the organ. 
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×

Sign Up

In Treatment

Maintenance/Hormone Treatment

Out of Treatment

Caregiver

Healthcare Professional

Not Applicable